Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.

Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.

Arthritis Rheumatol. 2019 Feb 28. doi: 10.1002/art.40874. [Epub ahead of print]

PMID:
30816640
2.

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6.

PMID:
29631782
3.

Data Standardization for Results Management.

Campbell RM, Dymshitz J, Eastwood BJ, Emkey R, Greenen DP, Heerding JM, Johnson D, Large TH, Littlejohn T, Montrose C, Nutter SE, Sawyer BD, Sigmund SK, Smith M, Weidner JR, Zink RW.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2017 Oct 20].

4.

Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.

Blanco MJ, Benesh DR, Knobelsdorf JA, Khilevich A, Cortez GS, Mokube F, Aicher TD, Groendyke TM, Marmsater FP, Tang TP, Johnson KW, Clemens-Smith A, Muhlhauser MA, Swanson S, Catlow J, Emkey R, Johnson MP, Schkeryantz JM.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):323-328. doi: 10.1016/j.bmcl.2016.11.049. Epub 2016 Nov 18.

PMID:
27908761
5.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.

Svensson KA, Heinz BA, Schaus JM, Beck JP, Hao J, Krushinski JH, Reinhard MR, Cohen MP, Hellman SL, Getman BG, Wang X, Menezes MM, Maren DL, Falcone JF, Anderson WH, Wright RA, Morin SM, Knopp KL, Adams BL, Rogovoy B, Okun I, Suter TM, Statnick MA, Gehlert DR, Nelson DL, Lucaites VL, Emkey R, DeLapp NW, Wiernicki TR, Cramer JW, Yang CR, Bruns RF.

J Pharmacol Exp Ther. 2017 Jan;360(1):117-128. Epub 2016 Nov 3.

6.

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.

Schenkel LB, Olivieri PR, Boezio AA, Deak HL, Emkey R, Graceffa RF, Gunaydin H, Guzman-Perez A, Lee JH, Teffera Y, Wang W, Youngblood BD, Yu VL, Zhang M, Gavva NR, Lehto SG, Geuns-Meyer S.

J Med Chem. 2016 Mar 24;59(6):2794-809. doi: 10.1021/acs.jmedchem.6b00039. Epub 2016 Mar 4.

PMID:
26942860
7.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

Hua Z, Bregman H, Buchanan JL, Chakka N, Guzman-Perez A, Gunaydin H, Huang X, Gu Y, Berry V, Liu J, Teffera Y, Huang L, Egge B, Emkey R, Mullady EL, Schneider S, Andrews PS, Acquaviva L, Dovey J, Mishra A, Newcomb J, Saffran D, Serafino R, Strathdee CA, Turci SM, Stanton M, Wilson C, Dimauro EF.

J Med Chem. 2013 Dec 27;56(24):10003-15. doi: 10.1021/jm401317z. Epub 2013 Dec 11.

PMID:
24294969
8.

Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.

Simard JR, Plant M, Emkey R, Yu V.

Assay Drug Dev Technol. 2013 Apr;11(3):152-62. doi: 10.1089/adt.2012.481. Epub 2013 Feb 14.

PMID:
23409774
9.

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

Yu V, Pistillo J, Archibeque I, Han Lee J, Sun BC, Schenkel LB, Geuns-Meyer S, Liu L, Emkey R.

Exp Hematol. 2013 May;41(5):491-500. doi: 10.1016/j.exphem.2013.01.005. Epub 2013 Jan 19.

PMID:
23340136
10.

FLIPRâ„¢ Assays for GPCR and Ion Channel Targets.

Arkin MR, Connor PR, Emkey R, Garbison KE, Heinz BA, Wiernicki TR, Johnston PA, Kandasamy RA, Rankl NB, Sittampalam S.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

11.

The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Epstein LF, Chen H, Emkey R, Whittington DA.

J Biol Chem. 2012 Oct 26;287(44):37447-57. doi: 10.1074/jbc.M112.391425. Epub 2012 Aug 29.

12.

Calcium metabolism and correcting calcium deficiencies.

Emkey RD, Emkey GR.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):527-56. doi: 10.1016/j.ecl.2012.04.019. Epub 2012 May 30. Review.

PMID:
22877428
13.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
14.

Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins.

Schneider S, Chen H, Tang J, Emkey R, Andrews PS.

Biochim Biophys Acta. 2012 Nov;1823(11):2038-45. doi: 10.1016/j.bbamcr.2012.03.018. Epub 2012 Apr 5.

15.

Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.

Bryan MC, Whittington DA, Doherty EM, Falsey JR, Cheng AC, Emkey R, Brake RL, Lewis RT.

J Med Chem. 2012 Feb 23;55(4):1698-705. doi: 10.1021/jm201565s. Epub 2012 Feb 9.

PMID:
22263917
16.

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.

Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, Wang HL, Wang SW, Wells MC, Wu B, Yu V, Liu L, Geuns-Meyer S.

J Med Chem. 2011 Dec 22;54(24):8440-50. doi: 10.1021/jm200911r. Epub 2011 Nov 16.

PMID:
22087750
17.

Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors.

Lo MC, Ngo R, Dai K, Li C, Liang L, Lee J, Emkey R, Eksterowicz J, Ventura M, Young SW, Xiao SH.

Anal Biochem. 2012 Feb 15;421(2):368-77. doi: 10.1016/j.ab.2011.10.014. Epub 2011 Oct 12.

PMID:
22056947
18.

High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.

Yu V, Fisch T, Long AM, Tang J, Lee JH, Hierl M, Chen H, Yakowec P, Schwandner R, Emkey R.

J Biomol Screen. 2012 Jan;17(1):27-38. doi: 10.1177/1087057111418228. Epub 2011 Aug 21.

PMID:
21859682
19.

Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor.

Drew AE, Al-Assaad S, Yu V, Andrews P, Merkel P, Szilvassy S, Emkey R, Lewis R, Brake RL.

J Biomol Screen. 2011 Feb;16(2):164-73. doi: 10.1177/1087057110394657.

PMID:
21297104
20.

Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.

Andrews PS, Schneider S, Yang E, Michaels M, Chen H, Tang J, Emkey R.

Assay Drug Dev Technol. 2010 Aug;8(4):471-87. doi: 10.1089/adt.2009.0264.

PMID:
20804422
21.

Screening G protein-coupled receptors: measurement of intracellular calcium using the fluorometric imaging plate reader.

Emkey R, Rankl NB.

Methods Mol Biol. 2009;565:145-58. doi: 10.1007/978-1-60327-258-2_7.

PMID:
19551361
22.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
23.

Quarterly intravenous ibandronate for postmenopausal osteoporosis.

Emkey RD.

Womens Health (Lond). 2008 May;4(3):219-28. doi: 10.2217/17455057.4.3.219. Review.

PMID:
19072470
24.

Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.

Marx IE, DiMauro EF, Cheng A, Emkey R, Hitchcock SA, Huang L, Huang MY, Human J, Lee JH, Li X, Martin MW, White RD, Fremeau RT Jr, Patel VF.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):31-5. doi: 10.1016/j.bmcl.2008.11.026. Epub 2008 Nov 13.

PMID:
19062274
25.

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.

Sebba AI, Emkey RD, Kohles JD, Sambrook PN.

Bone. 2009 Mar;44(3):423-7. doi: 10.1016/j.bone.2008.10.052. Epub 2008 Nov 12.

PMID:
19049913
26.

Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT Jr, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA.

J Med Chem. 2008 Aug 28;51(16):5019-34. doi: 10.1021/jm800463f. Epub 2008 Aug 5.

PMID:
18680277
27.

Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.

DiMauro EF, Buchanan JL, Cheng A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT Jr.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4267-74. doi: 10.1016/j.bmcl.2008.06.096. Epub 2008 Jul 3. Erratum in: Bioorg Med Chem Lett. 2009 Jan 1;19(1):284. Bioorg Med Chem Lett. 2008 Sep 15;18(18):5156.

PMID:
18640038
28.

Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign.

Binder C, Lafayette A, Archibeque I, Sun Y, Plewa C, Sinclair A, Emkey R.

Assay Drug Dev Technol. 2008 Feb;6(1):27-37. doi: 10.1089/adt.2007.111.

PMID:
18336085
29.

Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989.

Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Schindler JD.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S79-88. doi: 10.1002/art.23361.

30.

Safety considerations with bisphosphonates for the treatment of osteoporosis.

Strampel W, Emkey R, Civitelli R.

Drug Saf. 2007;30(9):755-63. Review.

PMID:
17722968
31.

Weekly oral alendronic Acid in male osteoporosis.

Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A.

Clin Drug Investig. 2004;24(6):333-41.

PMID:
17516720
32.

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.

Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.

Curr Med Res Opin. 2006 Sep;22(9):1745-55.

PMID:
16968578
33.

Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.

Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI, Emkey R, Hollinshead SP, Dell CP, Baker SR, Sher E.

J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17. Epub 2006 May 31.

PMID:
16738207
34.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
35.

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment.

Emkey R.

Womens Health (Lond). 2006 May;2(3):341-9. doi: 10.2217/17455057.2.3.341.

PMID:
19803906
36.

Improving compliance and persistence with bisphosphonate therapy for osteoporosis.

Emkey RD, Ettinger M.

Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. Review.

PMID:
16563937
37.

Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.

Epstein S, Delmas PD, Emkey R, Wilson KM, Hiltbrunner V, Schimmer RC.

Maturitas. 2006 Apr 20;54(1):1-10. Epub 2006 Mar 7. Review.

PMID:
16522358
38.

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D.

Curr Med Res Opin. 2005 Dec;21(12):1895-903.

PMID:
16368038
39.

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.

Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.

Ann Rheum Dis. 2006 May;65(5):654-61. Epub 2005 Dec 8. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

40.

Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.

Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, Wang H, Su EW, Mosior MK, Eacho PI, Cao G.

Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32.

PMID:
16018973
41.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR.

Curr Med Res Opin. 2005 Mar;21(3):391-401.

PMID:
15811208
42.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD.

Psychopharmacology (Berl). 2005 Apr;179(1):271-83. Epub 2005 Feb 17.

PMID:
15717213
44.

Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.

Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE.

Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. Review.

PMID:
15494040
45.

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C.

Osteoporos Int. 2004 Oct;15(10):792-8. Epub 2004 Apr 8.

PMID:
15071723
46.

Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group.

N Engl J Med. 2004 Mar 18;350(12):1189-99.

47.

Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.

Onyia JE, Galvin RJ, Ma YL, Halladay DL, Miles RR, Yang X, Fuson T, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, Bryant HU, Martin TJ.

J Pharmacol Exp Ther. 2004 Apr;309(1):369-79. Epub 2004 Jan 12.

PMID:
14718597
49.

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.

Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC.

J Clin Endocrinol Metab. 2003 Oct;88(10):4609-15.

PMID:
14557430
50.

Characterization of a novel G-protein coupled receptor from the parasitic nematode H. contortus with high affinity for serotonin.

Smith MW, Borts TL, Emkey R, Cook CA, Wiggins CJ, Gutierrez JA.

J Neurochem. 2003 Jul;86(1):255-66.

Supplemental Content

Support Center